Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Centre d'Investigation Clinique en Cancérologie (CI2C), Université de Nantes and INSERM CRNCA UMR 892, Nantes, France.
Eur J Haematol. 2013 Dec;91(6):552-6. doi: 10.1111/ejh.12183. Epub 2013 Sep 12.
Although targeted therapies are used increasingly in hematologic malignancies, we are unaware of any prior studies of radioimmunotherapy (RAIT) in B-acute lymphoblastic leukemia (ALL), even though this radiosensitive tumor expresses CD22, potentially a good target for this approach. Here, we report a patient with Philadelphia chromosome-positive B-ALL in third relapse who received RAIT with (90) yttrium ((90) Y)-labeled anti-CD22 epratuzumab tetraxetan. Seven weeks after initiating therapy, the patient achieved a BCR-ABL1 molecular remission documented by RT-qPCR, which is now continuing at 6 months while awaiting an allogeneic hematopoietic stem cell transplant. (90) Y-Epratuzumab tetraxetan may be a promising therapeutic option for CD22(+) B-ALL patients.
尽管靶向治疗在血液恶性肿瘤中的应用越来越多，但我们尚未发现针对 B 急性淋巴细胞白血病（ALL）的放射免疫治疗（RAIT）的研究，尽管这种对辐射敏感的肿瘤表达 CD22，可能是这种方法的一个很好的靶点。在这里，我们报告了一例费城染色体阳性 B-ALL 患者在第三次复发时接受了（90）钇（90）Y-标记的抗 CD22 依鲁替尼四嗪的 RAIT。在开始治疗后的 7 周，患者通过 RT-qPCR 达到了 BCR-ABL1 分子缓解，目前在等待异基因造血干细胞移植的同时继续缓解 6 个月。（90）Y-依鲁替尼四嗪可能是 CD22（+）B-ALL 患者有前途的治疗选择。
